Kisspeptin-10 Nasal Spray

Kisspeptin-10 is the shortest active piece of the kisspeptin family: the ten amino acids at the end of kisspeptin-54, which is made from the KISS1 gene. The family was first found as a metastasis suppressor gene and became famous in 2003 when two groups showed that people with a defective kisspeptin receptor (GPR54, now KISS1R) never enter puberty (Seminara and colleagues, New England Journal of Medicine 2003). Since then kisspeptin has been regarded as the real start button of the hormone axis, one step above GnRH.

This variant is the finished nasal spray: 10mg of kisspeptin-10 dissolved in 5ml of saline (NaCl) plus 0.4ml of bacteriostatic water, 5.4ml in total, which gives 1.85mg per ml. The pump delivers 0.1ml per spray, so 185mcg (about 0.19mg). That works out to 54 sprays on paper, about 50 once the pump is primed. No mixing, no syringe, no unit maths: the spray is filled fresh after you order. If you prefer working with the vial, the kisspeptin-10 entry has the calculator.

One thing to set expectations: almost all kisspeptin research comes from intravenous and subcutaneous dosing. The only nasal human study so far used the longer kisspeptin-54, not the kisspeptin-10 in this bottle. This entry tells you honestly what carries over and what does not.

This information is for research and educational purposes only. No medical advice.

Kisspeptin binds the KISS1R receptor on the GnRH neurons of the hypothalamus. Those neurons release GnRH, GnRH drives LH and FSH from the pituitary, LH stimulates testosterone production in the testes and FSH sperm maturation. In women the same chain governs follicle growth, oestradiol and ovulation. Kisspeptin therefore sits at the very top of the chain and works with the body's own pulsatility instead of overriding the pituitary directly.

In humans this is well documented. George and colleagues (Journal of Clinical Endocrinology and Metabolism 2011) gave healthy men intravenous boluses of 0.01 to 3 µg/kg: LH rose within 30 minutes in a dose-dependent way, most strongly at 1 µg/kg from 4.1 to 12.4 IU/l. The higher dose is the interesting part: 3 µg/kg produced less than 1 µg/kg, so more kisspeptin does not mean more response. A 22.5-hour infusion lifted testosterone from 16.6 to 24.0 nmol/l and increased the frequency and size of LH pulses. A head-to-head comparison by Jayasena and colleagues (Human Reproduction 2015) found that intravenous kisspeptin-10 and kisspeptin-54 released similar amounts of LH in men at the doses tested, while GnRH itself released about two to three times as much LH.

The catch is pharmacokinetics. In the mouse model of d'Anglemont de Tassigny and colleagues (PLoS One 2017), kisspeptin-10 left the blood with a half-life of about 4 minutes, kisspeptin-54 took 32 minutes. Even a kisspeptin-10 injection every 10 minutes for an hour did not sustain the LH response the way a single kisspeptin-54 dose did. Only kisspeptin-54 activated GnRH neurons behind the blood-brain barrier. Every dose of kisspeptin-10 is therefore a brief impulse, not a level. That explains why the community talks so much about timing and frequency. It also explains why the nasal route became interesting in the first place.

The nasal mucosa is thin and richly perfused. Small peptides like kisspeptin-10 can partly cross into the blood there, while the rest is broken down by mucosal peptidases or carried into the throat with the secretions and digested in the stomach. How much kisspeptin-10 actually arrives has never been measured. One spray at 185mcg contains more kisspeptin-10 than the intravenous bolus that maximally stimulated LH in men (1 µg/kg, about 70mcg for a 70kg person), but only an unknown fraction of that reaches the blood through the nose.

More exciting than blood uptake is a second route described by the Dhillo group in London in 2025 (Mills and colleagues, eBioMedicine 2025). The olfactory system contains its own population of GnRH neurons that connects to the GnRH neurons of the hypothalamus. In mice, fluorescently tagged kisspeptin accumulated in the olfactory epithelium after nasal dosing. The GnRH neurons of the olfactory bulb carry kisspeptin receptors. The nose may therefore be not just a detour into the blood but a direct line to the axis. So far this is shown for kisspeptin-54 in humans and mice; for kisspeptin-10 there is only a small rat study (Reviews on Clinical Pharmacology and Drug Therapy 2025) in which kisspeptin-10, given nasally or intraperitoneally, raised the levels of GnRH, kisspeptin and kisspeptin receptor in the hypothalamus and amygdala.

In practice: before first use, pump 2 to 3 times into the air until a fine mist appears. Gently clear your nose first, keep your head upright, point the nozzle slightly outward towards the nasal wall rather than at the septum, breathe in calmly and do not sniff hard. Avoid blowing your nose for 10 to 15 minutes afterwards. Two sprays in quick succession into the same nostril tend to run down the back rather than work twice as hard, so with two sprays use one per nostril. In the London study participants alternated nostrils for their four sprays and left 60 seconds between sprays, precisely so nothing ran out.

For kisspeptin-10 in humans, two papers from 2011 are the core. George and colleagues (Edinburgh) used intravenous boluses and infusions in healthy men to show the rapid, dose-dependent LH rise, the higher pulse frequency and the testosterone increase under infusion, with the side finding that the highest bolus dose did less than the middle one. Jayasena and colleagues (London) compared men and women: men responded to as little as 0.3 nmol/kg, women in the follicular phase not at all, not even to 32 nmol/kg subcutaneously, while women shortly before ovulation responded clearly. The axis is not a light switch; its sensitivity to kisspeptin depends on the hormonal milieu.

The nasal route has had a solid human study since 2025, but with the longer kisspeptin-54. Mills and colleagues (eBioMedicine 2025) gave kisspeptin-54 as a nasal spray to healthy men, healthy women and women with hypothalamic amenorrhoea in a randomised, double-blind crossover design. LH rose rapidly and dose-dependently, at 12.8 nmol/kg by a mean of 4.4 IU/l in men, 1.4 IU/l in women and 4.4 IU/l in the patients. Testosterone in men rose by 4.9 nmol/l with a peak at 150 minutes. No side effects occurred, blood pressure and heart rate stayed unchanged. The authors see it as the first non-invasive way to stimulate the axis with kisspeptin. For nasal kisspeptin-10, by contrast, there is only a small rat study from 2025 describing central effects on GnRH and the kisspeptin receptor in the brain, in a small specialist journal and with ELISA measurements rather than hormone profiles. Useful as a hint, not as proof.

Why people want to take kisspeptin nasally at all is shown by Comninos and colleagues (Journal of Clinical Investigation 2017). In 29 healthy men, a kisspeptin-54 infusion enhanced fMRI activity in limbic brain regions in response to sexual and couple-bonding stimuli, correlated with measures of reward and drive. It also attenuated negative mood. That is the origin of the idea of kisspeptin as a libido and mood peptide. Whether kisspeptin-10 can do the same is doubtful given the mouse data on the blood-brain barrier. Whether the nasal route changes that is exactly the open question. Anyone using the spray is ahead of the data, not behind it.

• Hormone axis: the desired effect is also the risk. LH, FSH, testosterone and, in women, oestradiol shift. In women the cycle may be affected. Anyone with a hormone-dependent condition (prostate, breast, endometriosis) or on hormone therapy is interfering with a running system and belongs in medical hands with that question.
• Blunting of the axis: constant stimulation makes the response smaller, not larger (Jayasena and colleagues 2009 and 2010): injected twice daily, the LH response had almost vanished after two weeks, while twice weekly it blunted only partially. Daily use for weeks is therefore not intended. In that study the pituitary remained responsive to GnRH, so the blunting concerns the kisspeptin response itself.
• Interactions: anyone taking testosterone or other androgens from outside has throttled the axis through feedback, so kisspeptin is likely to achieve little. GnRH analogues and GnRH antagonists block the chain one step lower. Kisspeptin does nothing there either. Do not use other nasal sprays (decongestants, steroid sprays) within the same quarter of an hour, they change the mucosa and uptake.
• Nose: burning, sneezing, a runny nose or a briefly stuffy feeling are possible with any spray, here mainly from the saline and the pump rather than the peptide. Pause if irritation persists or the nose bleeds.
• Circulation and general: in the human kisspeptin studies, intravenous, subcutaneous and nasal, no relevant side effects were reported. Blood pressure and heart rate stayed unchanged in the nasal study. Users occasionally report warmth, head pressure or mild dizziness shortly after a dose.
• Mood: according to the fMRI data kisspeptin engages limbic networks. Irritability, restlessness or a low mood after the effect wears off are theoretically conceivable; there are no data.
• Long-term data: the longest controlled human uses run over weeks, not years, the longest being eight weeks of twice-weekly subcutaneous kisspeptin-54 in women with hypothalamic amenorrhoea (Jayasena and colleagues, Clinical Pharmacology and Therapeutics 2010). There are no data for pregnancy, breastfeeding or adolescents. In adolescents the axis is still in motion anyway, so kisspeptin is off limits there.

The spray belongs in the fridge (2 to 8 degrees), not in the freezer and not in the door compartment where the temperature swings every time it opens. Protect it from light by leaving the bottle in its outer packaging or box. A few hours at room temperature, in the post or in a bag, do the solution no harm, but it should not sit warm for long.

Once opened, the solution keeps for several months in the fridge. The only measured series on a kisspeptin nasal spray comes from the London study: kisspeptin-54 in saline lost just over 5 percent of its concentration in the spray bottle at 4 degrees over 60 days, stayed clear and remained within the pharmaceutically accepted range without any stabilisers. There is no such series for kisspeptin-10 itself, but the London figure is still a useful guide. At 1 to 2 sprays on three days a week the bottle is empty after 2 to 4 months, which fits.

Wipe the nozzle with a clean tissue after each use and put the cap back on so nothing dries in and no germs migrate into the bottle. A bottle is personal, do not share it. If the solution turns gel-like, lumpy or smells different, stop using it. Slight cloudiness on its own is not a reason.